CTLA-4 polymorphisms are not associated with ocular inflammatory disease.

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is regarded with other molecules such as HLA, PTPN22 and CARD15 as genetic master switches of autoimmunity. Single nucleotide polymorphisms (SNPs) in the genes encoding these molecules have been associated with autoimmune conditions. We analysed the SNPs -318C/T and 49A/G in CTLA-4 in patients with Behcet's disease (BD), patients with intermediate uveitis and appropriate controls. Blood was collected from 236 patients with BD from the UK and the Middle East (ME), all fulfilling the International Study Group criteria for the diagnosis of BD, and 143 patients with idiopathic intermediate uveitis were recruited from the Medical Eye Unit at St Thomas' Hospital. Samples from healthy individuals from each geographical centre were used as controls. DNA was prepared by standard methods, and SNPs -318 and 49 in CTLA-4 were detected by a polymerase chain reaction-sequence specific primers (PCR-SSP) assay using primer mixes. The results showed that there was no association with either polymorphism in patients with BD from the UK or the ME. Similarly, there was no association in patients with intermediate uveitis. Moreover, there was no association with SNP in CTLA-4 and disease manifestations in BD or outcome in patients with intermediate uveitis. Both BD and intermediate uveitis have HLA associations, but there is no difference in distribution of CTLA-4 polymorphisms that are associated with other autoimmune diseases. The lack of association with polymorphisms in CTLA-4 and other master controlling genes of autoimmunity suggests that mechanisms that mediate such a description for BD and intermediate uveitis have still to be elucidated.

[1]  C. Robert,et al.  What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? , 2009, The oncologist.

[2]  J. Ioannidis,et al.  Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  P. Bagos,et al.  No evidence for association of CTLA-4 gene polymorphisms with the risk of developing multiple sclerosis: a meta-analysis , 2007, Multiple sclerosis.

[4]  E. Erken,et al.  Analysis of CD28 and CTLA‐4 gene polymorphisms in Turkish patients with Behcet's disease , 2007, International journal of immunogenetics.

[5]  M. Mochizuki,et al.  B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. , 2006, Investigative ophthalmology & visual science.

[6]  Paul Garside,et al.  Reversal of the TCR Stop Signal by CTLA-4 , 2006, Science.

[7]  Dennis McGonagle,et al.  A Proposed Classification of the Immunological Diseases , 2006, PLoS medicine.

[8]  J. Madrenas,et al.  A molecular perspective of CTLA-4 function. , 2006, Annual review of immunology.

[9]  T. Ogihara,et al.  The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multicenter collaborative study in Japan. , 2006, The Journal of clinical endocrinology and metabolism.

[10]  J. V. van Meurs,et al.  Polymorphisms in the T cell regulatory gene cytotoxic T lymphocyte antigen 4 influence the rate of acute rejection after liver transplantation , 2005, Gut.

[11]  J. Forrester,et al.  Cytokine gene polymorphism in sympathetic ophthalmia. , 2005, Investigative ophthalmology & visual science.

[12]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[13]  E. Alpsoy,et al.  CTLA‐4 gene 49A/G polymorphism in Turkish patients with Behçet's disease , 2005, Clinical and experimental dermatology.

[14]  Shizhong Han,et al.  Meta-analysis of the association of CTLA-4 exon-1 +49A/G polymorphism with rheumatoid arthritis , 2005, Human Genetics.

[15]  R. Vaughan,et al.  Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom? , 2005, British Journal of Ophthalmology.

[16]  A. Silman,et al.  Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. , 2005, Arthritis and rheumatism.

[17]  S. Gough,et al.  CTLA4 gene polymorphism and autoimmunity , 2005, Immunological reviews.

[18]  J. Harley,et al.  CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis , 2005, Human Genetics.

[19]  A. Gül Behçet's disease as an autoinflammatory disorder. , 2005, Current drug targets. Inflammation and allergy.

[20]  S. Rosenberg,et al.  Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. , 2004, Journal of immunotherapy.

[21]  Y. Tada,et al.  Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet's disease. , 2004, Rheumatology.

[22]  C. Polychronakos,et al.  A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele* , 2002, The Journal of Biological Chemistry.

[23]  G. Freeman,et al.  The B7–CD28 superfamily , 2002, Nature Reviews Immunology.

[24]  M. Fisfalen,et al.  CTLA-4 Gene Polymorphism at Position 49 in Exon 1 Reduces the Inhibitory Function of CTLA-4 and Contributes to the Pathogenesis of Graves’ Disease1 , 2000, The Journal of Immunology.

[25]  S. Pearce,et al.  CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. , 2000, Journal of hepatology.

[26]  F. Dammacco,et al.  Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. , 1999, Arthritis and rheumatism.

[27]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[28]  K. Usadel,et al.  CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.